ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer
University of Texas MD Anderson Cancer CenterAn MD Anderson-led Phase II trial showed the HER2-targeted therapy zanidatamab demonstrated durable responses in patients with advanced HER2-positive biliary tract cancer. The data were presented at the 2023 ASCO Annual Meeting.